Helen Sabzevari, PhD, of Precigen Connects Cancer and the Immune System on “Close to the Edge”

Precigen recently shared positive news on the clinical progress of five pipeline candidates. Three were developed using Precigen’s Ultra-CAR-T platform: PRGN-3005 being developed for advanced, recurrent platinum resistant ovarian cancer; PRGN-3006 for relapsed or refractory acute myeloid leukemia; and PRGN-3007, for which the FDA has cleared IND application to launch a Phase I/Ib open-label trial in advanced ROR1+ hematological and solid tumors . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge

Previous articleResearchers Uncover a Form of Four-Stranded DNA that Plays a Role in Cockayne Syndrome
Next articleDiverse Ancestries Yield More Predictive Genetic Risk Scores for Heart Disease